Depomed inks $50M licensing deal on Proquin

Esprit Pharma will pay $50 million for US sales and marketing rights to Proquin XR, Depomed's recently approved extended-release treatment for urinary tract infections. In addition to the $50 million licensing fee--including a $30 million upfront payment--Esprit will pay 15 percent to 25 percent royalties on net sales. Esprit also has right of refusal for marketing rights in Canada.

- read this release for more